TIDMCOG

RNS Number : 8231X

Cambridge Cognition Holdings PLC

01 September 2022

Cambridge Cognition Holdings Plc

(" Cambridge Cognition" or the "Company")

Cambridge Cognition wins GBP2.2 million neurodegenerative disease trial

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that it has won a GBP2.2 million contract providing cognitive assessments and electronic diaries for a neurodegenerative disease trial. Revenue from the contract is expected over the next two financial years. This is a follow-on sale from a GBP2.1 million contract announced by the Company on 2 February 2022 with the same customer.

One person develops dementia every three minutes(1) , making neurodegenerative diseases a key target for drug development. To develop effective treatments, sensitive and specific cognitive assessments are essential as cognitive dysfunction is a hallmark of neurodegenerative diseases. With unrivalled use in over 2,500 peer-reviewed publications, and a reputation for excellent customer service, Cambridge Cognition has been selected as the cognitive assessment partner for this series of treatment trials.

In delivering the contract, Cambridge Cognition will provide the technology for a hybrid trial, combining in-clinic with at home cognitive assessments. This will enable the Company to offer more detailed insights into the development of disease over time and the efficacy of new pharmaceutical compounds.

Commenting, Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

"We are pleased to have further strengthened our relationship with this pharmaceutical customer that is committed to tackling neurodegenerative disease. Cambridge Cognition has a strong history of delivering cognitive assessments in the field, traditionally in clinics and now also at home. The quick succession of large contracts from this customer is a testament to both the efficacy of our products and quality of our service."

References

   1.        https://www.alzheimers.org.uk/about-us/news-and-media/facts-media

For further information, contact:

 
 Cambridge Cognition Holdings Plc               Tel: 012 2381 0700 
  Matthew Stork, Chief Executive Officer         press@camcog.com 
  Stephen Symonds, Chief Financial Officer 
 Panmure Gordon (UK) Limited (NOMAD and Joint   Tel: 020 7886 2968 
  Broker)                                        (Corporate Finance) 
  Freddy Crossley / Emma Earl                    (Corporate Broking) 
  Rupert Dearden 
 Dowgate Capital Limited (Joint Broker)         Tel: 020 3903 7715 
  David Poutney / James Serjeant 
 IFC Advisory Ltd (Financial PR and IR)         Tel: 020 3934 6630 
  Tim Metcalfe / Graham Herring / Zach Cohen

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CNTBUGDICSXDGDB

(END) Dow Jones Newswires

September 01, 2022 02:00 ET (06:00 GMT)

Cambridge Cognition (AQSE:COG.GB)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas Cambridge Cognition.
Cambridge Cognition (AQSE:COG.GB)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas Cambridge Cognition.